{"id":"symbicort-turbuhaler-160-4-5","safety":{"commonSideEffects":[{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Palpitations"},{"rate":null,"effect":"Oral candidiasis"},{"rate":null,"effect":"Nervousness"},{"rate":null,"effect":"Muscle cramps"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Budesonide is a corticosteroid that suppresses inflammatory responses in the airways by binding to glucocorticoid receptors, reducing mucus production and airway edema. Formoterol is a long-acting beta-2 agonist that binds to beta-2 adrenergic receptors on bronchial smooth muscle, causing relaxation and bronchodilation. Together, they provide both anti-inflammatory and bronchodilatory effects for sustained asthma and COPD control.","oneSentence":"Symbicort combines a long-acting beta-2 agonist (formoterol) and an inhaled corticosteroid (budesonide) to reduce airway inflammation and improve bronchial smooth muscle relaxation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:10:34.277Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Asthma maintenance therapy"},{"name":"Chronic obstructive pulmonary disease (COPD) maintenance therapy"}]},"trialDetails":[{"nctId":"NCT06473779","phase":"PHASE3","title":"Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2024-09-30","conditions":"Severe Asthma","enrollment":326},{"nctId":"NCT06429475","phase":"PHASE3","title":"Anti-Inflammatory Reliever South Africa","status":"RECRUITING","sponsor":"University of KwaZulu","startDate":"2024-06-06","conditions":"Asthma","enrollment":1038},{"nctId":"NCT03888131","phase":"PHASE3","title":"Foster® pMDI (CHF 1535) Versus Symbicort® Turbohaler in COPD Patient","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2018-07-30","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":750},{"nctId":"NCT06568445","phase":"PHASE4","title":"Maintenance at Initial Treatment With Sequential Anti-Inflammation Reliever Therapy","status":"NOT_YET_RECRUITING","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2024-08-12","conditions":"Bronchial Asthma","enrollment":90},{"nctId":"NCT02062463","phase":"PHASE3","title":"Study to Evaluate the Mastery of Inhaler Technique for Budesonide Formoterol (BF) SPIROMAX® as Compared to SYMBICORT® TURBOHALER® as Treatment for Adult Participants With Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2014-05-28","conditions":"Asthma","enrollment":485},{"nctId":"NCT01803555","phase":"PHASE3","title":"Efficacy and Safety Evaluation of Budesonide/Formoterol SPIROMAX® Inhalation Powder Versus SYMBICORT® TURBOHALER®","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2013-07-04","conditions":"Asthma","enrollment":605},{"nctId":"NCT00576069","phase":"","title":"Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma","status":"RECRUITING","sponsor":"Gelb, Arthur F., M.D.","startDate":"2007-10-25","conditions":"Asthma","enrollment":60},{"nctId":"NCT01225913","phase":"PHASE4","title":"Mechanism(s) of Airflow Limitation During Exacerbation of Asthma","status":"RECRUITING","sponsor":"Gelb, Arthur F., M.D.","startDate":"2007-10","conditions":"Asthma","enrollment":50},{"nctId":"NCT04215848","phase":"PHASE3","title":"As-needed Budesonide/Formoterol Turbuhaler in Stepping Down Period","status":"COMPLETED","sponsor":"Hat Yai Medical Education Center","startDate":"2020-04-01","conditions":"Asthma","enrollment":31},{"nctId":"NCT02237508","phase":"PHASE1","title":"A Clinical Study to Evaluate Z7200 (Budesonide/Formoterol) Pharmacokinetics Profile in Healthy Volunteers","status":"COMPLETED","sponsor":"Zambon SpA","startDate":"2014-09","conditions":"Asthma","enrollment":90},{"nctId":"NCT02631941","phase":"PHASE1","title":"Clinical Study to Evaluate Z7200 Pharmacokinetics Profile","status":"COMPLETED","sponsor":"Zambon SpA","startDate":"2016-01","conditions":"Asthma","enrollment":91},{"nctId":"NCT02227394","phase":"PHASE2","title":"Study to Compare the Effects of Z7200 And Symbicort® Turbohaler on Respiratory Imaging Parameters in Asthmatic Patients","status":"COMPLETED","sponsor":"Zambon SpA","startDate":"2014-08","conditions":"Asthma, Asthma Chronic, Asthma Bronchial","enrollment":20},{"nctId":"NCT01070888","phase":"PHASE4","title":"Trial on the Effect of Budesonide/Formoterol and Inhaled Budesonide Alone on Exercise-Induced Asthma","status":"TERMINATED","sponsor":"Boston Children's Hospital","startDate":"2010-02","conditions":"Exercise Induced Asthma","enrollment":6},{"nctId":"NCT03197818","phase":"PHASE3","title":"Active Controlled Trial of CHF5993 Pressurized Metered-dose Inhaler ( pMDI) vs Symbicort®Turbuhaler® in Patients With Chronic Obstructive Pulmonary Disease ( COPD)","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2016-12-14","conditions":"COPD (Chronic Obstructive Pulmonary Disease)","enrollment":990},{"nctId":"NCT01253473","phase":"PHASE4","title":"Symbicort in Airway Predominant Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"National Jewish Health","startDate":"2012-04","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":46},{"nctId":"NCT00915538","phase":"PHASE4","title":"Comparing Bronchodilation of Symbicort With and Without Valved Holding Chamber (Aerochamber Plus)","status":"COMPLETED","sponsor":"Western Sky Medical Research","startDate":"2009-07","conditions":"Asthma","enrollment":16},{"nctId":"NCT04494321","phase":"PHASE1","title":"A Bioequivalence Pivotal Study of SYN010 HFA Inhaler and Symbicort® 160/4.5 in Healthy Volunteers Without Charcoal Block","status":"COMPLETED","sponsor":"Intech Biopharm Ltd.","startDate":"2017-06-19","conditions":"Asthma, COPD","enrollment":99},{"nctId":"NCT02224157","phase":"PHASE3","title":"A Clinical Study to Evaluate Symbicort Turbuhaler Used 'as Needed' in Adults and Adolescents With Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-11-28","conditions":"Asthma","enrollment":4215},{"nctId":"NCT02149199","phase":"PHASE3","title":"A Clinical Study to Evaluate Symbicort Turbuhaler Used 'as Needed' in Adults and Adolescents With Asthma.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-07-07","conditions":"Asthma","enrollment":3850},{"nctId":"NCT02934607","phase":"PHASE1","title":"A Study to Assess How Much Drug Reaches the Blood When Given From Symbicort pMDI With Spacer Compared to That of Symbicort pMDI Without Spacer in Healthy Volunteers","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2016-11-04","conditions":"Study is Being Conducted in Healthy Volunteers","enrollment":50},{"nctId":"NCT02533505","phase":"PHASE4","title":"Phase IV O2 Consumption Study in COPD Patients.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-08-25","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":51},{"nctId":"NCT02757209","phase":"NA","title":"Comparative Study on Usability of Inhaler Devices in Adults With Asthma or COPD","status":"COMPLETED","sponsor":"Consorzio Futuro in Ricerca","startDate":"2016-04","conditions":"Asthma, COPD","enrollment":84},{"nctId":"NCT02157935","phase":"PHASE3","title":"Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-06-27","conditions":"COPD Patients","enrollment":2026},{"nctId":"NCT01760304","phase":"PHASE4","title":"Changes in Cardiac Function in COPD Patients After Administration of Budesonide/Formoterol (Symbicort®) Versus Placebo","status":"TERMINATED","sponsor":"Brigham and Women's Hospital","startDate":"2012-01","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":5},{"nctId":"NCT02725242","phase":"PHASE3","title":"Efficacy of Once-daily Budesonide/Formoterol Turbuhaler 4.5/160 µg in Step Down Asthma","status":"COMPLETED","sponsor":"Hat Yai Medical Education Center","startDate":"2016-03","conditions":"Asthma","enrollment":77},{"nctId":"NCT03073057","phase":"PHASE1","title":"Pharmacokinetic Study to Compare Absorption of Budesonide/Formoterol Easyhaler and Symbicort Turbuhaler","status":"COMPLETED","sponsor":"Orion Corporation, Orion Pharma","startDate":"2016-01","conditions":"Asthma","enrollment":20},{"nctId":"NCT01444430","phase":"PHASE3","title":"A 6 Month Safety Study Comparing Symbicort With Inhaled Corticosteroid Only in Asthmatic Adults and Adolescents","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2011-12","conditions":"Asthma","enrollment":12460},{"nctId":"NCT00479739","phase":"PHASE4","title":"CONCEPT: A 1-Year Comparison Of A Stable Dose Of SERETIDE® Inhaler With An Adjustable Maintenance Dose Of SYMBICORT® Inhaler. SERETIDE® Inhaler is a Trademark of GSK Group of Companies. SYMBICORT® Inhaler is a Trademark of Astra Zeneca.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2002-11","conditions":"Asthma","enrollment":700},{"nctId":"NCT02850484","phase":"PHASE1","title":"A Bioequivalence Pivotal Study of SYN010 HFA Inhaler and Symbicort® 160/4.5 in Healthy Volunteers With Charcoal Block","status":"COMPLETED","sponsor":"Intech Biopharm Ltd.","startDate":"2016-03","conditions":"Asthma, Chronic Obstructive Pulmonary Disease (COPD)","enrollment":99},{"nctId":"NCT01070784","phase":"PHASE3","title":"A Safety and Efficacy Study of Symbicort Turbuhaler Compared With Standard Chronic Obstructive Pulmonary Disease (COPD) Treatment in Japan","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-01","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":328},{"nctId":"NCT01136655","phase":"PHASE2","title":"A Study in Asthmatic Children (6 to <12 Yrs) Comparing Single Doses of Formoterol and Foradil® Evaluating Efficacy","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-09","conditions":"Asthma","enrollment":54},{"nctId":"NCT01602523","phase":"PHASE3","title":"Effect of Symbicort on Sleep Quality in Patients With Emphysema","status":"UNKNOWN","sponsor":"Temple University","startDate":"2011-03","conditions":"Emphysema, Poor Sleep Quality","enrollment":40},{"nctId":"NCT00839800","phase":"PHASE3","title":"Study to Investigate the Efficacy of Symbicort® SMART.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-02","conditions":"Asthma","enrollment":2091},{"nctId":"NCT00702325","phase":"PHASE4","title":"Phase4/Symbicort® Versus Pulmicort Flexhaler® in African Americans","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-06","conditions":"Asthma","enrollment":311},{"nctId":"NCT00419952","phase":"PHASE3","title":"A Comparison of SYMBICORT® pMDI With Budesonide HFA pMDI in African American Subjects With Asthma.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-02","conditions":"Asthma","enrollment":742},{"nctId":"NCT01069289","phase":"PHASE3","title":"Efficacy and Safety Study of Symbicort® Turbuhaler® Versus Oxis® Turbuhaler® in Chronic Obstructive Pulmonary Disease (COPD) Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-01","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":1293},{"nctId":"NCT00837967","phase":"PHASE3","title":"Study to Investigate the Safety and Efficacy of High Dose of Symbicort® SMART in Japanese Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-01","conditions":"Asthma","enrollment":25},{"nctId":"NCT00419757","phase":"PHASE3","title":"An Efficacy Study Comparing SYMBICORT® Pressurised Metered Dose Inhaler (pMDI) With Budesonide Hydrofluoroalkanes (HFA) pMDI, in Hispanic Subjects With ICS Dependent Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-01","conditions":"Asthma","enrollment":558},{"nctId":"NCT00989833","phase":"PHASE2","title":"Comparing Symbicort® As-Needed or Bricanyl As-Needed or Pulmicort® Once Daily + Bricanyl As-Needed in Asthma Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-09","conditions":"Exercise Induced Asthma","enrollment":66},{"nctId":"NCT00628758","phase":"PHASE3","title":"A Comparison of Symbicort® Single Inhaler Therapy and Conventional Best Practice for the Treatment of Persistent Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2005-12","conditions":"Asthma","enrollment":430},{"nctId":"NCT00939341","phase":"PHASE4","title":"Study to Investigate Real Life Effectiveness of Symbicort Maintenance and Reliever Therapy in Asthma Patients Across Asia","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-07","conditions":"Asthma","enrollment":862},{"nctId":"NCT00242775","phase":"PHASE3","title":"Comparison of the Efficacy/Safety of Symbicort® Turbuhaler®,Seretide™ Diskus™ 50/500 µg & Terbutaline Turbuhaler® 0.4 mg","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2005-05","conditions":"Asthma","enrollment":2100},{"nctId":"NCT00252785","phase":"PHASE3","title":"Efficacy & Safety of Symbicort® TURBUHALER® 160/4.5 µg Twice Daily & Pulmicort® TURBUHALER® 200 µg Twice Daily + Theolong® Tablet 200 mg Twice Daily in Japanese Asthmatic Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2005-10","conditions":"Asthma","enrollment":340},{"nctId":"NCT00290264","phase":"PHASE3","title":"SALTO - Symbicort Single Inhaler Therapy Use in Adolescent Adults and Adults With Persistent Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2004-12","conditions":"Asthma","enrollment":1000},{"nctId":"NCT00244608","phase":"PHASE3","title":"A Comparison of the Control of Asthma Provided by Symbicort® Turbuhaler® Versus Symbicort® Turbuhaler® Plus Pulmicort® Turbuhaler® Plus Terbutaline Turbuhaler®","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2005-05","conditions":"Asthma","enrollment":100},{"nctId":"NCT00252824","phase":"PHASE3","title":"STYLE - Symbicort Single Inhaler Therapy vs Conventional Therapy in Treatment of Persistent Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2005-07","conditions":"Asthma","enrollment":1000},{"nctId":"NCT00651651","phase":"PHASE3","title":"Efficacy of Symbicort Versus Its Monocomponents - SPRUCE 80/4.5","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2002-08","conditions":"Asthma","enrollment":450},{"nctId":"NCT00326053","phase":"PHASE3","title":"Prevention of Asthma Relapse After Discharge From Emergency","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-05","conditions":"Asthma","enrollment":600},{"nctId":"NCT00242411","phase":"PHASE4","title":"MONO: Symbicort® Single Inhaler Therapy and Conventional Best Standard Treatment for the Treatment of Persistent Asthma in Adolescents and Adults","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2004-09","conditions":"Asthma","enrollment":1900},{"nctId":"NCT00652002","phase":"PHASE3","title":"Efficacy of Symbicort Versus Its Monocomponents - SPRUCE 160/4.5","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2002-07","conditions":"Asthma","enrollment":450},{"nctId":"NCT00288379","phase":"PHASE3","title":"SMILDA - Symbicort®Turbuhaler® Allergan Challenge Study in Allergic Patients With Mild Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2004-10","conditions":"Asthma","enrollment":16},{"nctId":"NCT00255255","phase":"PHASE3","title":"Safety & Efficacy of Symbicort® Turbuhaler® (1, 2, and 4 x 160/4.5 µg Twice Daily) in Japanese Patients With Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2005-11","conditions":"Asthma","enrollment":120},{"nctId":"NCT00385593","phase":"PHASE3","title":"Symbicort Single Inhaler Therapy vs Conventional Best Practice for the Treatment of Persistent Asthma in Adults","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2006-09","conditions":"Asthma, Bronchial","enrollment":654},{"nctId":"NCT00576316","phase":"PHASE4","title":"Symbicort Maintenance and Reliever Therapy - Experience in Real Life Setting in Malaysia","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-01","conditions":"Asthma","enrollment":201},{"nctId":"NCT00419744","phase":"PHASE3","title":"A Comparison of SYMBICORT® pMDI With Formoterol Turbuhaler® in Subjects With COPD","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-01","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":1200},{"nctId":"NCT00524641","phase":"","title":"Asthma Control-A \"Patient Follow up Programme\" Maintenance and Reliever Therapy in a Single Inhaler","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-07","conditions":"Asthma","enrollment":1254},{"nctId":"NCT00206154","phase":"PHASE3","title":"A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and Symbicort® pMDI 2 x 80/4.5 μg Bid With Formoterol Turbuhaler®, Budesonide pMDI, the Combination of Formoterol Turbuhaler® and Budesonide pMDI, and Placebo in COPD Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2005-04","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":1500},{"nctId":"NCT00206167","phase":"PHASE3","title":"A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and 2 x 80/4.5 μg Bid With Formoterol Turbuhaler® 2 x 4.5 μg Bid and Placebo in Patients With COPD","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2005-04","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":1600},{"nctId":"NCT00867737","phase":"PHASE4","title":"Onset of Action of Advair Hydrofluoroalkane (HFA) 115/21 in Comparison to Symbicort Pressurised Metered-Dose Inhalers (pMDI) 160/4.5 Measured by Impulse Oscillometry (IOS)","status":"UNKNOWN","sponsor":"Allergy and Asthma Center of El Paso","startDate":"2008-09","conditions":"Asthma","enrollment":30},{"nctId":"NCT00252863","phase":"PHASE3","title":"DESOLO - SiT Peri-Launch: A Comparison of Symbicort Single Inhaler Therapy and Conventional Best Practice for the Treatment of Persistent Asthma in Adults","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2004-12","conditions":"Asthma","enrollment":1600}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Symbicort Turbuhaler 160/4.5","genericName":"Symbicort Turbuhaler 160/4.5","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Symbicort combines a long-acting beta-2 agonist (formoterol) and an inhaled corticosteroid (budesonide) to reduce airway inflammation and improve bronchial smooth muscle relaxation. Used for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD) maintenance therapy.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}